Lucid Diagnostics Inc - Asset Resilience Ratio
Lucid Diagnostics Inc (LUCD) has an Asset Resilience Ratio of 6.09% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Lucid Diagnostics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2022)
This chart shows how Lucid Diagnostics Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Lucid Diagnostics Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lucid Diagnostics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lucid Diagnostics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.59 Million | 6.09% |
| Total Liquid Assets | $2.59 Million | 6.09% |
Asset Resilience Insights
- Limited Liquidity: Lucid Diagnostics Inc maintains only 6.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lucid Diagnostics Inc Industry Peers by Asset Resilience Ratio
Compare Lucid Diagnostics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Lucid Diagnostics Inc (2019–2022)
The table below shows the annual Asset Resilience Ratio data for Lucid Diagnostics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 4.09% | $1.33 Million | $32.51 Million | +2.20pp |
| 2021-12-31 | 1.89% | $1.12 Million | $59.00 Million | -3.48pp |
| 2020-12-31 | 5.38% | $118.00K | $2.19 Million | -6.05pp |
| 2019-12-31 | 11.42% | $118.09K | $1.03 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more